Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke (RESPECT-ETB)
A Multicentric, Randomized, Double-blind, Parallel, Placebo-controlled Phase III Study to Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke.
Sponsor: Pharmazz, Inc.
A PHASE3 clinical study on Acute Ischemic Stroke and Cerebral Stroke, this trial is actively recruiting participants. The trial is conducted by Pharmazz, Inc. and has accumulated 14 data snapshots since 2025. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
14 versions recorded-
Jan 2026 — Present [monthly]
Recruiting PHASE3
-
Dec 2025 — Jan 2026 [monthly]
Recruiting PHASE3
-
Nov 2025 — Dec 2025 [monthly]
Recruiting PHASE3
-
Oct 2025 — Nov 2025 [monthly]
Recruiting PHASE3
-
Sep 2025 — Oct 2025 [monthly]
Recruiting PHASE3
▶ Show 9 earlier versions
-
Aug 2025 — Sep 2025 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Jun 2025 — Aug 2025 [monthly]
Not Yet Recruiting PHASE3
-
Jan 2025 — Jun 2025 [monthly]
Not Yet Recruiting PHASE3
-
Sep 2024 — Jan 2025 [monthly]
Not Yet Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Not Yet Recruiting PHASE3
-
Nov 2023 — Jul 2024 [monthly]
Not Yet Recruiting PHASE3
-
Aug 2023 — Nov 2023 [monthly]
Not Yet Recruiting PHASE3
-
Apr 2023 — Aug 2023 [monthly]
Not Yet Recruiting PHASE3
-
Feb 2023 — Apr 2023 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Pharmazz, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
A Coruña, Spain , Albacete, Spain , Altenburg, Germany , Badajoz, Spain , Badalona, Spain , Barakaldo, Spain , Barcelona, Spain , Berlin, Germany , Bridgeton, United States , Bury, United Kingdom and 25 more locations